EMEA-000499-PIP04-17 - paediatric investigation plan

veliparib

Key facts

• Active substance:
  veliparib
• Therapeutic area:
  Oncology
• Decision number:
  P/0063/2018
• PIP number:
  EMEA-000499-PIP04-17
• Pharmaceutical form(s):
  • Capsule, hard
  • Age appropriate oral liquid dosage formulation
  • Tablet
• Condition(s) / indication(s):
  Treatment of lung carcinoma (small cell and non-small cell carcinoma)
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  16/03/2018
• Compliance check done:
  No

Decision

P/0063/2018: EMA decision of 16 March 2018 on the granting of a product- specific waiver for veliparib (EMEA-000499-PIP04-17)

Adopted Reference Number: EMA/105839/2018